Sartorius (SRT) CMD 2026 summary

Strategic direction, innovation, and market positioning

• Focus on accelerating drug development through automation, AI, advanced cell models, and digitalization to meet demand for efficient, cost-effective therapies and adapt to regulatory shifts away from animal testing.

• Maintain leadership in single-use technologies, process intensification, and expand into advanced therapy solutions, bioanalytics, and cell analytics, supported by targeted R&D, M&A, and strategic partnerships with industry leaders.

• Emphasize customer-centric innovation, operational excellence, and digital transformation, including AI-powered data analytics and automation across workflows.

• Commitment to a pure-play biopharma focus, leveraging a global manufacturing and distribution network for resilience and proximity to customers.

• Address evolving biopharma R&D needs, including advanced cell models and predictive, human-relevant testing solutions.

Financial guidance, performance, and growth targets

• Midterm guidance targets 8%-11% organic group revenue growth, with 9%-12% in bioprocessing and 5%-7% in lab products and services, aiming to outpace addressable market growth of 7%-9%.

• EBITDA margin expansion of 50-75 basis points per year expected at group level, with Bioprocess Solutions Division at 60–85 bps and Lab Products & Services at 20–30 bps, driven by operational leverage, cost discipline, and digitalization.

• CapEx normalization anticipated post-2026/2027, returning to historical levels (~9% of turnover), following major investments in global capacity.

• Strong free cash flow generation projected, with disciplined capital allocation prioritizing organic deleveraging, selective M&A, and a dividend policy aligned with historical payout ratios.

• Double-digit EPS growth expected, supported by increasing capacity utilization, automation, and operating leverage, with an efficiency program targeting €100m cost savings in 2025.

Market outlook, trends, and growth drivers

• Bioprocessing market expected to grow 8%-10%, with single-use technologies and process intensification as key growth levers, especially in commercial manufacturing.

• Lab products and services market to grow 4%-6%, with double-digit growth in advanced cell models and toxicology testing.

• Biopharma market growth driven by aging population, increased drug approvals, and shift to biologics, projected to reach 57% of global pharma sales by 2030.

• Pipeline of 26,000 molecules, with ~50% in next-gen antibodies and advanced therapies, underpins future demand for innovative solutions.

• Regulatory shifts and technological advances (AI, automation) create new business opportunities in lab workflows and toxicity testing.